Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2023
Reporting Period: Second Quarter ended June 30, 2023
Context: The filing announces the Company's financial results for the quarter ended June 30, 2023, and provides a corporate update. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. The filing references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Outlook and Commentary: The Company provided a "corporate update" alongside the financial results, but the specific content of this update is not included in the filing text.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the provided text.
Legal Status: The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for Q2 2023.
- Verify the specific details of the "corporate update" mentioned in the filing to understand current operational status.
- Check the Company's cash runway and burn rate, as these are critical for emerging growth biopharmaceutical companies not reporting revenue in the summary.
- Confirm if there were any changes in clinical trial progress or regulatory milestones during the quarter.